ISSN: 2044-9038 (Print) 2044-9046 (Electronic)

Clinical Practice

Antirheumatic Drugs Peer-review Journals

Disease-modifying antirheumatic drugs (DMARDs) are a gaggle of medicines commonly utilized in people with atrophic arthritis. A number of these drugs also are utilized in treating other conditions like Marie-Strumpell disease, rheumatoid arthritis, and systemic LE. The most recent drugs for the treatment of atrophic arthritis are the Janus kinase (JAK) inhibitors, which are FDA approved under the brand names Rinvoq, Olumiant and Xeljanz. PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Rheumatoid arthritis (RA) is the second most common type of arthritis, affecting about 1.5 million Americans. It’s an inflammatory disease that’s caused by an autoimmune condition. The disease occurs when your body attacks its own healthy joint tissues. This results in redness, inflammation, and pain. The main goal of RA drugs is to block inflammation. This helps prevent joint damage. OMICS International is a pioneer in organizing international conferences and leading the scientific event organizer, which organises over 100 Scientific Conferences all over the globe annually with the support from various scientific associations. Since its inception, OMICS International has focused on meeting the needs of the scientific community, through strong tie-up with business and industry, while at the same time accomplishing international benchmarks and accreditation standards.     

High Impact List of Articles

Relevant Topics in Clinical